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and hospital complications. We examined the development of early invasive treatment
in patients with NSTE-ACS over the time of 2 years by dividing the population into 4
periods of 6 months, according to date of admission.
Results: During the study period, a total of 11,550 patients with NSTE-ACS were
enrolled. Over the time period of 2 years the prevalence of prior PCI and diabetes
increased whereas prior MI as well as prior stroke and renal failure decreased. No
differences were found in age, gender and clinical presentation with cardiogenic shock.
From 2006 to 2008 the number of patients with NSTE-ACS undergoing coronary
angiography significantly increased from initially 55.7% to finally 64.5%. At the same
time more patients did undergo PCI in the acute setting of NSTE-ACS. No differences
were found in clinical outcome (death / MI / stroke) between the 4 time periods of 6
months each.
Conclusion: Between 2006 and 2008 the number of NSTE-ACS patients undergoing
coronary angiography and PCI significantly increased in clinical practice in Europe.
No differences were found in in-hospital clinical endpoints between the 4 time periods
of 6 months.
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Background: Pulmonary disease (CPD) increases the long-term risk of adverse
outcomes in patients with acute coronary syndromes (ACS). CPD is associated with
systemic inflammatory response and increased risk of thrombotic events. Patient with
ACS and CPD are less likely to receive the medications recommended by guidelines
such as beta-blockers.
Methods: Aim of the study was to evaluate the influence of CPD on in-hospital
outcome and use of revascularization procedures in patients with ACS included into
ACS III Registry (2006-2008) of the Euro Heart Survey Programme which enrolled
21,872 consecutive patients including 40.5% with STEMI/LBBB MI.
Results: In population of 21,872 patients with ACS history of CPD was present in
1672 (7.7%) of patients. Patients with CPD were older (71.4 vs. 66.0, p<0.01) and
more frequently male (69 vs. 66.5%, p=0.037), had more often diabetes (30.4 vs.
26.3%, p<0.01), chronic renal disease (13,2 vs. 5,9, p<0.01), heart failure (20.1 vs.
8.6%, p<0.01), history of myocardial infarction (33 vs. 23, p<0.01), stroke (9,6 vs.
5,6%, p<0.01) and previous PCI (16 vs. 13,8%, p=0.01) than patients without CPD.
PCI was performed significantly less in patients with CPD (37,7 vs. 53,7%, p<0,001)
including primary PCI in STEMI (36,2 vs. 58,1, p<0.01) and urgent PCI in NSTE-
ACS (27,8 vs. 34,6%, p<0,01). CPD group had more often multivessel disease (33,1
vs. 25,1%, p<0.01). During hospitalization patients received less ASA (93,1 vs. 94,3%,
p=0,034), clopidogrel (76,1 vs. 83,5%, p<0,01) and GPIIbIIIa antagonists (15,6 vs.
20,4%, p<0,01). In hospital outcome and bleeding events are shown in table.
In-hospital outcome
*CHI2 OR KRUSKAL-WALLIS
Conclusion: In patients with ACS and chronic pulmonary disease the antithrombotic
medications recommended by guidelines (ASA, clopidogrel, GPIIbIIa antagonists) are
underused. Patients with CPD have increased in-hospital mortality as well as risk of
heart failure, reinfarction and bleeding.
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Background: Use of vitamin K antagonists (VKA) can increase the risk of bleeding
in particular in patients presenting with acute coronary syndromes (ACS) treated
aggresively with antithrombotic medications.
Methods: Aim was to evaluate the effects of chronic use of VKA on in-hospital
outcome of patients with ACS included into ACS III Registry (2006-2008) of the Euro
Heart Survey Programme which enrolled 21,872 consecutive patients including 40.5%
with STEMI/LBBB MI. In 19,075 patients the data on chronic use of VKA/antiplatelet
medications prior to admission was documented.
Results: In population of 19,075 patients 634 (3.3%) received chronically VKA.
Patients treated with VKA were older (74.9 vs. 66.4, p<0.01), more often had diabetes
(37.2 vs. 27.2%, p<0.01), atrial fibrillation (43,8 vs. 6,1, p<0.01), chronic renal disease
(18.7 vs 6.2%, p<0.01), heart failure (26.2 vs. 9.1%, p<0.01) and stroke (14,8 vs. 5,3%,
p<0.01) and previous PCI (25.9 vs. 14,2%, p<0.01). Significantly more patients on
VKA had moderate (45,6 vs. 40,4%, p<0.02) or severe (17,1 vs. 7,3%, p<0.01) left
ventricular dusfunction. There were no differences between VKA and non-VKA
patients in use of PCI (54,6 vs. 55,8, p=053)and DES (22,3 vs. 24,2, p=0,47), however
use of ASA (86,3 vs. 94,4%, p<0,01), clopidogrel (75,5 vs. 84,4%, p<0,01) and
GPIIIbIIIa (13,2 vs. 20,3%, p<0,01) was less in VKA-patients. Patients on VKA had
significantly higher risk of in-hospital death, heart failure, major and minor bleeding,
but not intracranial bleeding and puncture site bleeding (Table)
In-hospital outcome
*CHI2 OR KRUSKAL-WALLIS
Conclusion: CONCLUSION: Patients with ACS who were on chronic anticoagulation
with VKA receive less aggressive antithrombotic treatment however risk of minor and
major bleeding is increased. Patients on VKA had significantly higher in-hospital
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